

## **EXHIBIT B**

### **Relevant Executory Contracts**

	<b>Contract Description</b>
1	Continuing Guaranty and Indemnity Agreement executed by Purdue Pharma L.P. in favor of AmerisourceBergen Drug Corporation (“ <u>ABDC</u> ,” and, collectively with related entities, “ <u>ABDC Entities</u> ” <sup>17</sup> ), dated February 3, 2005, as amended, restated, supplemented or modified from time to time
2	Drug Distribution Service Agreement by and among Purdue Pharma L.P., associated U.S. companies, and certain ABDC Entities, effective as of April 1, 2006 and: <ul style="list-style-type: none"> <li>• extension letter dated December 19, 2012</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>
3	Distribution Performance Agreement by and among Purdue Pharma L.P. and certain of its associated U.S. companies, and certain ABDC Entities, effective as of October 1, 2012, and: <ul style="list-style-type: none"> <li>• Amendment to Distribution Performance Agreement effective as of September 30, 2014,</li> <li>• Second Amendment to Distribution Performance Agreement effective as of September 30, 2015</li> <li>• Third Amendment to Distribution Performance Agreement effective as of September 28, 2018</li> <li>• Fourth Amendment to Distribution Performance Agreement effective as of October 1, 2019</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>
4	Authorized Distributor Agreement by and among Purdue Pharma L.P. and certain of its associated U.S. companies, and certain ABDC Entities, effective as of October 1, 2012, and: <ul style="list-style-type: none"> <li>• Amendment to Authorized Distributor Agreement effective as of September 30, 2014</li> <li>• Second Amendment to Authorized Distributor Agreement effective as of September 30, 2015</li> <li>• Third Amendment to Authorized Distributor Agreement effective as of September 1, 2017</li> <li>• Fourth Amendment to Authorized Distributor Agreement effective as of October 1, 2019</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>

<sup>17</sup> In addition to ABDC, the ABDC Entities include the following entities: (1) AmerisourceBergen Corporation in its individual; (2) ABDC as successor in interest to Belco Drug Corp.; (3) Integrated Commercialization Solutions, Inc.; (4) American Medical Distributors, Inc.; capacity; (5) J.M. Blanco, Inc.; (6) MWI Veterinary Supply, Inc.; (7) PharMEDium Services, LLC; (8) H.D. Smith Holdings LLC; (9) H.D. Smith, LLC; and (10) Valley Wholesale Drug Co., LLC.

	<b>Contract Description</b>
5	<p>Logistical Services Agreement by and among Purdue Pharma L.P. and certain of its associated U.S. companies, and certain ABDC Entities, effective as of November 1, 2015, and:</p> <ul style="list-style-type: none"> <li>• Second Amendment to Logistics Services Agreement effective as of October 1, 2019</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>
6	<p>Master Distribution Services Agreement between Rhodes Pharmaceuticals LP and certain ABDC Entities, effective as of January 1, 2015, and:</p> <ul style="list-style-type: none"> <li>• PrxO Generics Program Addendum to Master Distribution Services Agreement, effective as of January 1, 2015</li> <li>• Addendum to Master Distribution Services Agreement, effective as of January 1, 2015</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>
7	<p>Distribution Services Agreement between Rhodes Pharmaceuticals LP and certain ABDC Entities, effective as of March 16, 2015, and:</p> <ul style="list-style-type: none"> <li>• Amendment to Distribution Services Agreement effective as of January 20, 2017</li> <li>• modification letter dated January 9, 2017</li> <li>• Second Amendment to Distribution Services Agreement effective as of March 16, 2020</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>
8	<p>Master Distribution Services Agreement between Rhodes Pharmaceuticals LP and certain ABDC Entities, effective as of January 1, 2018, and:</p> <ul style="list-style-type: none"> <li>• PrxO Generics Program Addendum to Master Distribution Services Agreement effective as of January 1, 201</li> <li>• Pharmagen Generics Program Addendum to Master Distribution Services Agreement effective as of January 1, 2018</li> <li>• as further amended, restated, supplemented or modified from time to time</li> </ul>
9	<p>Continuing Guaranty and Indemnification Agreement executed by Purdue Pharma L.P. in favor of the ABDC Entities effective as of October 1, 2019</p>